ro5045337
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2007 (NCT00559533)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- p53-binding protein Mdm-2INHIBITOR
MDM2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ro5045337
- ro5045337
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01677780 | Phase 1 | Nov 1, 2012 | Roche |
| NCT01605526 | Phase 1 | May 1, 2012 | Roche |
| NCT01164033 | Phase 1 | Aug 1, 2010 | Roche |
| NCT01143740 | Phase 1 | Jun 1, 2010 | Roche |
| NCT00623870 | Phase 1 | May 1, 2008 | Roche |
| NCT00559533 | Phase 1 | Dec 1, 2007 | Roche |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 6 | 6 | 1 | 2007 |
1 organizations
Page 1 / 1